Open access

Research Article

14 February 2020

Adding pertuzumab to adjuvant therapy for high-risk HER2-positive early breast cancer in APHINITY: a GRADE analysis

Authors: Alberto Zambelli [email protected], Giovanni Pappagallo, and Paolo MarchettiAuthor Info & Affiliations

Publication: Journal of Comparative Effectiveness Research

Volume 9, Number 6

https://doi.org/10.2217/cer-2019-0168

PDF OtherFormats

Abstract

Aim: Adding pertuzumab to standard trastuzumab-based adjuvant therapy significantly improved invasive disease-free survival (IDFS) in the APHINITY trial. However, the magnitude of benefit was marginal in the overall population. Methods: We used GRADE (Grading of Recommendations Assessment, Development and Evaluation) analysis on data from APHINITY to build summary-of-findings tables to evaluate the efficacy, safety and quality of evidence of predefined clinical outcomes for the addition of pertuzumab to trastuzumab-based adjuvant therapy in patients with high-risk HER2-positive early breast cancer. Results: Pertuzumab significantly improved 3-year, event-free, absolute benefit in disease-free survival, IDFS and distant relapse-free interval (DFRI) in patients with node-positive or hormone receptor-negative disease. The analysis provides strength of evidence supporting the addition of pertuzumab in this patient population.

Supplementary Material

File (suppl_file.docx)

Download
2.09 MB

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest

1.

Cossetti RJ, Tyldesley SK, Speers CH, Zheng Y, Gelmon KA. Comparison of breast cancer recurrence and outcome patterns between patients treated from 1986 to 1992 and from 2004 to 2008. J. Clin. Oncol. 33(1), 65–73 (2015).

• Interesting paper illustrating the changing patterns over time of relapse according to estrogen receptor and HER2 status.

2.

Moja L, Tagliabue L, Balduzzi S et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst. Rev. (4), CD006243 (2012).

3.

Cameron D, Piccart-Gebhart MJ, Gelber RD et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075), 1195–1205 (2017).

•• Updated data from the pivotal randomized trial that led to the first approvacl for a HER2-targeted therapy.

4.

Perez EA, Romond EH, Suman VJ et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J. Clin. Oncol. 32(33), 3744–3752 (2014).

5.

Slamon D, Eiermann W, Robert N, Giermek J, Martin M, Jasiowka M. Ten-year follow-up of BCIRG-006 comparing doxorubicin plus cyclophosphamide followed by docetaxel with doxorubicin plus cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2-positive early breast cancer patients [Abstract S5-04]. Presented at San Antonio Breast Cancer Symposium December 11. TX, USA, 76(suppl. 4), S5–04 (2016).

6.

Dall P, Koch T, Gohler T et al. Trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: results of a prospective, noninterventional study on routine treatment between 2006 and 2012 in Germany. Oncologist 22(2), 131–138 (2017).

7.

Von Minckwitz G, Procter M, De Azambuja E et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377(2), 122–131 (2017).

•• The sole trial of the addition of pertuzumab to trastuzumab in the adjuvant setting in early HER2-positive breast cancer. The focus of the GRADE analysis carried out in this paper.

8.

Denduluri N, Chavez-Macgregor M, Telli ML et al. Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36(23), 2433–2443 (2018).

• Current clinical practice guidelines detailing recommendations for the use of pertuzumab in early breast cancer.

9.

Curigliano G, Burstein HJ, Winer EP et al. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 28(8), 1700–1712 (2017).

• Current clinical practice guidelines detailing recommendations for the use of pertuzumab in early breast cancer.

10.

Guyatt GH, Oxman AD, Vist GE et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650), 924–926 (2008).

11.

GRADEpro GDT. GRADEpro Guideline Development Too(2018). http://gdt.gradepro.org

• Methodology of the GRADE method for ranking the effects and quality of evidence for clinical outcomes.

12.

Guyatt GH, Oxman AD, Kunz R et al. GRADE guidelines: 2. Framing the question and deciding on important outcomes. J. Clin. Epidemiol. 64(4), 395–400 (2011).

13.

Hudis CA, Barlow WE, Costantino JP et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J. Clin. Oncol. 25(15), 2127–2132 (2007).

14.

Brozek JL, Akl EA, Alonso-Coello P et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 64(5), 669–677 (2009).

15.

Miller KD. Questioning our APHINITY for More. N. Engl. J. Med. 377(2), 186–187 (2017).

• Interesting editorial discussing the challenges of translating, at the individual level, the finite advantage of pertuzumab in the setting.

16.

Gianni L, Pienkowski T, Im YH et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, Phase II trial. Lancet Oncol. 13(1), 25–32 (2012).

• A Phase II randomized trial that provides the first evidence for the benefit of pertuzumab in early HER2-positive breast cancer. Further trials in the same setting followed to investigate strategies to improve pathological responses with pertuzumab.

17.

Cortazar P, Zhang L, Untch M et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384(9938), 164–172 (2014).

18.

Broglio KR, Quintana M, Foster M et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol. 2(6), 751–760 (2016).

19.

Von Minckwitz G, Huang CS, Mano MS et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N. Engl. J. Med. 380(7), 617–628 (2019).

20.

Martin M, Holmes FA, Ejlertsen B et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, Phase III trial. Lancet Oncol. 18(12), 1688–1700 (2017).

21.

Lagakos SW. The challenge of subgroup analyses – reporting without distorting. N. Engl. J. Med. 354(16), 1667–1669 (2006).

22.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine – reporting of subgroup analyses in clinical trials. N. Engl. J. Med. 357(21), 2189–2194 (2007).

23.

Howie LJ, Scher NS, Amiri-Kordestani L et al. FDA approval summary: pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin. Cancer Res. 25(10), 2949–2955 (2018).

24.

Dowsett M, Cuzick J, Ingle J et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J. Clin. Oncol. 28(3), 509–518 (2010).

25.

De Laurentiis M, Cancello G, D'Agostino D et al. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26(1), 44–53 (2008).

|